CMS Open Payments · Program Year 2024
PolarisAR Inc
PolarisAR Inc reported $25,931.40 across General Payments, Research, and Ownership to 11 physicians and teaching hospitals across 12 transactions.
- $25.9K Below-median payer
- All-tracks total
- 12 Below-median volume
- Transactions
- 11 Below-median reach
- Recipients
- #1491
- of 1,925 companies
PolarisAR Inc reported $25,931.40 across all CMS Open Payments tracks (General + Research + Ownership) to 11 physicians and teaching hospitals in Program Year 2024 - ranking #1491 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $22,581.40, averaging $2.4K per recipient.
How PolarisAR Inc's $25.9K all-tracks total breaks down
PolarisAR Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer polarisar-inc PolarisAR Inc
$25.9K · #1491/1,925 · 0.0% industry · PY2024
- TOT $25.9K
- RANK #1491
- SHARE 0.0%
- TXN 12
- RCP 11
- CAT 2
- GEN $22.6K
- TOP1 49.7%
- PY 2024
Volume peers
Nearest volume peer: Boehringer Ingelheim USA, Inc. ($26.0K)
PolarisAR Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for PolarisAR Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For PolarisAR Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $20.7K across 10 transactions, 91.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
PolarisAR Inc made 2 types of general payments. "Consulting Fee" is the largest category at $20.7K, 91.8% of General Payments.
How PolarisAR Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $20.7K | 10 | 91.8% |
| Travel and Lodging | $1.8K | 1 | 8.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $22,581.40 (100.0%) of $22,581.40 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for PolarisAR Inc
The five named recipients with the highest reported General Payments from this company
- 1
Herbert John Cooper
$11,234.00 across 5 reported transactions
- 2
Nana owusu Sarpong
$9,500.00 across 5 reported transactions
- 3
Peter Aaron Gold
$1,847.40 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
PolarisAR Inc ranks #1491 of 1,925 by total payments (bottom 23% by spend) but is notably more concentrated than that alone would suggest -- #426 of 1,838 by HHI (top 23% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Eton Pharmaceuticals, Inc. : $80.6K total payments, HHI 4392
- Circinus Medical Technology LLC : $5.3K total payments, HHI 4376
- Kinamed, Inc. : $23.8K total payments, HHI 4353
- Joline Medical Inc : $2.6K total payments, HHI 4318
- Cepheid : $408.4K total payments, HHI 4315
- Hoya Surgical Optics, Inc : $11.7K total payments, HHI 4312
- PolarisAR Inc (this company) : $22.6K total payments, HHI 4312
- Medicem Inc. : $119.3K total payments, HHI 4304
- Oasis Medical, Inc. : $94.3K total payments, HHI 4288
- Consortium of Independent Immunology Clinics, LLC : $225.3K total payments, HHI 4285
- Evolved By Nature, Inc. : $239.3K total payments, HHI 4275
- Cochlear Ltd : $10.1K total payments, HHI 4273
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as PolarisAR Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about PolarisAR Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with PolarisAR Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Enduromed, Llc
Axis Spine Technologies Inc.
Sc Medica
Topcon Corporation
Aucta Pharmaceuticals, Inc.
Put this to use
PolarisAR Inc ranks #1491 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just PolarisAR Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.